A swathe of online and print media coverage for The Genome Odyssey by Euan Ashley, Professor of Medicine and Genetics and the Associate Dean at Stanford University.
There has been substantial media coverage for a new book by Euan Ashley, the Professor of Medicine and Genetics and the Associate Dean at Stanford University.
His book details how rare genetic quirks are being harnessed to fight disease and bolster the body’s natural defence system.
We told how a groundbreaking new vaccine based on the DNA code of Olympic athletes and other ‘superhumans’ could transform society within a decade by providing lifelong protection against three of the top 10 leading causes of death.
According to Professor Ashley, the so-called “superhero” jab could offer simultaneous, long-term protection against heart disease, stroke, and Alzheimer’s disease—as well as liver disease—thanks to “bold and breathtaking” advances in genetic engineering.
It will deliver the blueprint of ‘ideal’ cells from men and women whose genes are more disease-resistant than those of the average person, together with an ‘instruction manual’ to help the body “repair, tweak and improve” its own versions. The ‘manual’ includes multiple versions of a ‘gene editor’, a tool like a word processor, which alters just one letter of DNA from a disease-prone version to a disease-resistant version.
A single dose could lead to a “body-wide genetic upgrade” that would cut the risk of premature death in some adults by as much as 50 per cent.
Clinical trials of individual components are expected to begin by 2026, and the combination vaccine to become available within 10 to 15 years.
Professor Euan Ashley, above, reveals how a “superhero” vaccine could give a “body-wide genetic upgrade” and protect against three of the world’s top 10 leading causes of death.
The Genome Odyssey: Medical Mysteries and the Incredible Quest to Solve by Professor Euan Ashley is out now. Complimentary media review copies are available through Palamedes PR
The vaccine would be administered to those in serious clinical need before being rolled out— possibly on the NHS—to the wider population, potentially including to children.
If breakthroughs in genome research and technology continue to evolve at the same rapid pace, the vaccine – which could benefit tens of millions of people worldwide – could be widely available worldwide in just 10 years, he says.
Professor Ashley, 49, is the founding director of Stanford’s Center for Inherited
Cardiovascular Disease and its Clinical Genomics Program, which researches new treatments for patients with genetic heart syndromes, the co-director of Stanford Medicine Catalyst, which develops medical innovation through technology, and one of the heads of the Stanford Center for Undiagnosed Diseases, which identifies rare genetic medical conditions.
He is widely considered to be one of the world’s foremost authorities on genetic
engineering and as a pioneer in the application of gene sequencing in medicine.
His new book, The Genome Odyssey: Medical Mysteries and the Incredible Quest to Solve Them is out now and available for media review through Palamedes PR.